nuclear medicine

Top Story

Biotechnology firm acquires imaging technology license to improve acute coronary syndrome diagnosis

A biotechnology company’s licensing deal for a radiopharmaceutical could make it easier to diagnose¬†acute coronary syndrome in cases that might otherwise go undiagnosed or be diagnosed too late. Molecular Targeting Technologies acquired the license for the radiopharmaceutical diagnostic imaging agent from the Medical College of Wisconsin, according to a company statement. It is used in […]